Literature DB >> 25335885

Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Brenda A Wilson, Mengfei Ho1.   

Abstract

Delivering therapeutic cargos to specific cell types in vivo poses many technical challenges. There is currently a plethora of drug leads and therapies against numerous diseases, ranging from small molecule compounds to nucleic acids to peptides to proteins with varying binding or enzymatic functions. Many of these candidate therapies have documented potential for mitigating or reversing disease symptoms, if only a means for gaining access to the intracellular target were available. Recent advances in our understanding of the biology of cellular uptake and transport processes and the mode of action of bacterial protein toxins have accelerated the development of toxin-based cargo-delivery vehicle platforms. This review provides an updated survey of the status of available platforms for targeted delivery of therapeutic cargos, outlining various strategies that have been used to deliver different types of cargo into cells. Particular emphasis is placed on the application of toxin-based approaches, examining critical issues that have hampered realization of post-intoxication antitoxins against botulism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25335885      PMCID: PMC4410985          DOI: 10.2174/1568026614666141022094517

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  160 in total

1.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications.

Authors:  J Mark Sutton; Jonathan Wayne; Anthony Scott-Tucker; Susan M O'Brien; Philip M H Marks; Frances C G Alexander; Clifford C Shone; John A Chaddock
Journal:  Protein Expr Purif       Date:  2005-03       Impact factor: 1.650

3.  Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.

Authors:  A Boberg; S Gaunitz; A Bråve; B Wahren; N Carlin
Journal:  Vaccine       Date:  2008-04-24       Impact factor: 3.641

4.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

Review 5.  Immunotoxin treatment of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

6.  Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.

Authors:  Om P Edupuganti; Saak V Ovsepian; Jiafu Wang; Tomas H Zurawski; James J Schmidt; Leonard Smith; Gary W Lawrence; J Oliver Dolly
Journal:  FEBS J       Date:  2012-06-14       Impact factor: 5.542

7.  Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.

Authors:  Andreas Rummel
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

8.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

9.  Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.

Authors:  Nicholas R Silvaggi; David Wilson; Saul Tzipori; Karen N Allen
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

10.  Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.

Authors:  Dirk Dressler; Sebastian Paus; Andrea Seitzinger; Bernd Gebhardt; Andreas Kupsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-05-18       Impact factor: 10.154

View more
  5 in total

1.  Modular domain swapping among the bacterial cytotoxic necrotizing factor (CNF) family for efficient cargo delivery into mammalian cells.

Authors:  Elizabeth E Haywood; Mengfei Ho; Brenda A Wilson
Journal:  J Biol Chem       Date:  2018-01-25       Impact factor: 5.157

2.  Cell-penetrating peptides derived from Clostridium difficile TcdB2 and a related large clostridial toxin.

Authors:  Jason L Larabee; Garrett D Hauck; Jimmy D Ballard
Journal:  J Biol Chem       Date:  2017-12-15       Impact factor: 5.157

3.  Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Authors:  Yongfeng Fan; Isin N Geren; Jianbo Dong; Jianlong Lou; Weihua Wen; Fraser Conrad; Theresa J Smith; Leonard A Smith; Mengfei Ho; Melissa Pires-Alves; Brenda A Wilson; James D Marks
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

Review 4.  Strategies for Targeted Delivery to the Peripheral Nerve.

Authors:  Kelly A Langert; Eric M Brey
Journal:  Front Neurosci       Date:  2018-11-27       Impact factor: 4.677

5.  Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.

Authors:  Yongfeng Fan; Jianbo Dong; Jianlong Lou; Weihua Wen; Fraser Conrad; Isin N Geren; Consuelo Garcia-Rodriguez; Theresa J Smith; Leonard A Smith; Mengfei Ho; Melissa Pires-Alves; Brenda A Wilson; James D Marks
Journal:  Toxins (Basel)       Date:  2015-08-26       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.